By dampening inflammation-driven indoleamine-2,3-dioxygenase (IDO) activity, these interventions may preserve tryptophan availability for serotonin synthesis, reducing neurotoxic kynurenine metabolites that have been implicated in depression and fatigue [42]. This evidence concerns the gene IDO1 and depressive disorder.